达沙替尼治疗系统性硬化症相关间质性肺疾病中的新型肺成像生物标志物和皮肤基因表达亚型

数据集获取（Figshare）

• 源站标题：Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease
• DOI：10.1371/journal.pone.0187580
• 发布日期：2017-11-09
• 文件数：15 个
• 文件总体积：1.96 MB
• 源站页面：https://plos.figshare.com/articles/dataset/Novel_lung_imaging_biomarkers_and_skin_gene_expression_subsetting_in_dasatinib_treatment_of_systemic_sclerosis-associated_interstitial_lung_disease/5587801

命令行下载

curl -L -o "S1 Checklist.doc" "https://ndownloader.figshare.com/files/9719737"
curl -L -o "S1 File.pdf" "https://ndownloader.figshare.com/files/9719740"
curl -L -o "S1 Table.docx" "https://ndownloader.figshare.com/files/9719752"
curl -L -o "S2 Table.docx" "https://ndownloader.figshare.com/files/9719776"
curl -L -o "S3 Table.docx" "https://ndownloader.figshare.com/files/9719791"
curl -L -o "S4 Table.docx" "https://ndownloader.figshare.com/files/9719803"
curl -L -o "S5 Table.docx" "https://ndownloader.figshare.com/files/9719815"
curl -L -o "S6 Table.docx" "https://ndownloader.figshare.com/files/9719824"

文件清单

• S1 Checklist.doc（223.74 KB）
• S1 File.pdf（676.86 KB）
• S1 Table.docx（16.86 KB）
• S2 Table.docx（14.42 KB）
• S3 Table.docx（14.34 KB）
• S4 Table.docx（15.13 KB）
• S5 Table.docx（15.49 KB）
• S6 Table.docx（14.30 KB）
• S7 Table.docx（14.82 KB）
• S8 Table.xlsx（85.33 KB）
• S9 Table.docx（15.25 KB）
• S10 Table.docx（14.71 KB）
• S1 Fig.pdf（117.85 KB）
• S2 Fig.pdf（346.62 KB）
• S3 Fig.pdf（375.61 KB）

文件总体积 1.96 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
There are no effective treatments or validated clinical response markers in systemic sclerosis (SSc). We assessed imaging biomarkers and performed gene expression profiling in a single-arm open-label clinical trial of tyrosine kinase inhibitor dasatinib in patients with SSc-associated interstitial lung disease (SSc-ILD).
Methods
Primary objectives were safety and pharmacokinetics. Secondary outcomes included clinical assessments, quantitative high-resolution computed tomography (HRCT) of the chest, serum biomarker assays and skin biopsy-based gene expression subset assignments. Clinical response was defined as decrease of >5 or >20% from baseline in the modified Rodnan Skin Score (MRSS). Pulmonary function was assessed at baseline and day 169.
Results
Dasatinib was well-tolerated in 31 patients receiving drug for a median of nine months. No significant changes in clinical assessments or serum biomarkers were seen at six months. By quantitative HRCT, 65% of patients showed no progression of lung fibrosis, and 39% showed no progression of total ILD. Among 12 subjects with available baseline and post-treatment skin biopsies, three were improvers and nine were non-improvers. Improvers mapped to the fibroproliferative or normal-like subsets, while seven out of nine non-improvers were in the inflammatory subset (p = 0.0455). Improvers showed stability in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), while both measures showed a decline in non-improvers (p = 0.1289 and p = 0.0195, respectively). Inflammatory gene expression subset was associated with higher baseline HRCT score (p = 0.0556). Non-improvers showed significant increase in lung fibrosis (p = 0.0313).
Conclusions
In patients with SSc-ILD dasatinib treatment was associated with acceptable safety profile but no significant clinical efficacy. Patients in the inflammatory gene expression subset showed increase in skin fibrosis, decreasing pulmonary function and worsening lung fibrosis during the study. These findings suggest that target tissue-specific gene expression analyses can help match patients and therapeutic interventions in heterogeneous diseases such as SSc,

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0187580（source: https://plos.figshare.com/articles/dataset/Novel_lung_imaging_biomarkers_and_skin_gene_expression_subsetting_in_dasatinib_treatment_of_systemic_sclerosis-associated_interstitial_lung_disease/5587801）。